ReadyTech Holdings Ltd
ReadyTech Holdings Ltd is a provider of people management software for educators, employers, and facilitators of career transitions. Its products are JR Plus, A2E, HR3, ePayroll, JR Gov, Aussiepay, and others. The company's operating segments include Education and Work pathways, Workforce Solutions, and Government and Justice. It generates maximum revenue from the Government and Justice. The education segment mainly provides products and services to tertiary education providers. Its Workforce segment provides products and services to a mid-sized company across various industries. The Government division provides government and justice case management software as a service solution to local governments, state governments, and justice departments.
相关临床试验
374
50 进行中
药物批准
185
批准总数
监管机构
4
监管机构数
成立时间
N/A
进行中（未招募）
16
4.3%
已完成
285
76.2%
尚未招募
34
9.1%
招募中
24
6.4%
终止
2
0.5%
Unknown
12
3.2%
撤回
1
0.3%
- India's three Production Linked Incentive schemes for pharmaceuticals, bulk drugs and medical devices have drawn ₹46,744 crore in actual pharma investment against a ₹17,275 crore target as of June 2026. - The bulk drugs scheme has commissioned 39 projects covering 28 APIs, enabling domestic production of Penicillin-G, Clavulanic Acid and Rifampicin that were previously largely imported. - The medical devices scheme has started production of 57 unique devices including MRI machines, CT scanners, Cath Labs and linear accelerators, with a 5 per cent incentive on incremental sales for five years. - Global manufacturers including GE Healthcare, Siemens, Philips, Varex, Nipro and Omron have established or expanded Indian manufacturing operations under the schemes.
- A CDSCO subject expert committee recommended on August 11 waiving local Phase III trials and bioequivalence studies for generic injectable lenacapavir, citing unmet medical need. - Emcure Pharmaceuticals has filed its injectable version with the DCGI and expects approval by the end of the fiscal year, with Dr Reddy's Laboratories and Hetero also developing generics. - The generics are being developed under royalty-free voluntary licences from Gilead Sciences signed in 2024 covering 120 countries, with MSF expecting rollout in licensed low- and middle-income markets from 2027.
- Takeda Biopharmaceuticals India and Dr Reddy's Laboratories have entered a distribution agreement covering QDENGA, India's first approved dengue vaccine, in the country's private market. - Dr Reddy's will exclusively promote and distribute QDENGA for paediatric and adult vaccination, with availability anticipated in the first half of 2027 pending local authority processes. - The deal follows CDSCO marketing authorisation in July 2026 for individuals aged 4 to 60 years, and Takeda retains public-market rights plus medical and brand oversight. - Dengue cases in India have risen 11-fold over two decades, and a nationwide ICMR surveillance study found all four serotypes co-circulating, with 1 in 14 patients infected with multiple serotypes.
- Dr. Reddy's Laboratories has launched NIVORZ, a nivolumab biosimilar to Opdivo, in India, marking its entry into the country's biosimilar immuno-oncology segment. - The Drugs Controller General of India approved NIVORZ across 12 indications spanning solid and haematological malignancies, including metastatic non-small cell lung cancer and melanoma. - A multi-country programme in 288 patients, 252 from India and 36 from Russia, showed comparable efficacy, safety, pharmacokinetics and immunogenicity to reference nivolumab. - The Indian immuno-oncology market was estimated at approximately Rs. 3,900 crore in 2025, driven predominantly by checkpoint inhibitors such as nivolumab and pembrolizumab.
- Immutep will narrow registration-directed development of eftilagimod alfa to head and neck squamous cell carcinoma with CPS below one and neoadjuvant soft tissue sarcoma. - The pivot follows early discontinuation of TACTI-004 and a root cause analysis identifying subtle N-glycan structural differences between 200-litre and 2,000-litre efti batches. - Immutep has contracted a new 200-litre manufacturing run, the scale used for ten GMP batches in earlier successful Phase I and Phase II studies. - New studies are targeted to begin in the second half of 2027, subject to trial design, regulatory discussions, manufacturing timelines, partnering and resources.
- Aspen's distribution of Eli Lilly's Mounjaro in South Africa generated roughly R1.5 billion in sales, accounting for about 40% of growth in the country's private pharmaceutical market over the past year. - CEO Stephen Saad said GLP-1 medicines have the potential to become Aspen's biggest product category, with plans to expand Mounjaro into Nigeria, Kenya, and other African markets. - Aspen received Canadian regulatory approval in July for generic injectable semaglutide and expects first sales in the 2027 financial year, pending active ingredient supply from Dr. Reddy's Laboratories. - Saad expects generic GLP-1 medicines globally to cost at least 50% less than branded options, potentially widening access to obesity and diabetes treatments.
- India's Subject Expert Committee recommended waiving local Phase III and bioequivalence trials for generic lenacapavir PrEP from Dr. Reddy's and Emcure Pharmaceuticals. - The waiver applies only to the HIV prevention (PrEP) indication, not to treatment of multidrug-resistant HIV-1, which requires additional pharmacokinetic and ethnicity data. - Marketing authorization would be conditional on mandatory post-marketing Phase IV efficacy studies, with protocols due to CDSCO within three months. - Lenacapavir, a first-in-class long-acting capsid inhibitor, showed zero infections in PURPOSE 1 and a 96% incidence reduction in PURPOSE 2.
- Dr. Reddy's Laboratories has terminated its distribution and promotion agreement with Novartis India Limited for select brands in India, originally signed on February 11, 2022. - The termination was triggered by a change in the controlling shareholding of Novartis India Limited. - Dr. Reddy's will continue to commercialize the affected brands through an extended transition period until September 30, 2026. - The strategic move aims to streamline operations and ensure an orderly market transition for the covered product portfolio.
- Dr. Reddy's Laboratories has registered an innovative PD-1 immunotherapy in South Africa for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare and aggressive head and neck cancer. - The registration addresses a critical unmet need, as treatment options for RM-NPC have remained limited despite oncology advances over the past decade. - Unlike traditional chemotherapy, immunotherapy enables the body's immune system to recognize and fight cancer cells, representing a significant advancement for difficult-to-treat cancers. - Nasopharyngeal carcinoma is often diagnosed at an advanced stage because early symptoms resemble common illnesses such as persistent nasal congestion, hearing loss, and swollen lymph nodes.
- Dr Reddy's Laboratories received US FDA approval for its rituximab biosimilar, a monoclonal antibody targeting CD20 on B lymphocytes. - Fresenius Kabi holds exclusive US commercialization rights under an agreement with Dr Reddy's. - The biosimilar is indicated for B-cell malignancies including non-Hodgkin lymphoma and chronic lymphocytic leukemia, plus certain autoimmune conditions. - The product is already commercialized in India, the EU, the UK, and over 25 emerging markets, with additional approvals in Switzerland and Canada.
